Celldex vaccine rindopepimut cuts death risk from brain cancer, study shows

Printer Friendly

November 25, 2015

A new study presented at the Society for Neuro-Oncology conference last week reported that the cancer vaccine rindopepimut has been shown to reduce the risk of death for glioblastoma (GBM) patients by 47 percent. This is the first time an immunotherapy treatment, which leverages the body's own immune system to fight tumors, has improved the survival rate in a randomized study of glioblastoma patients. Additional findings of this 74-patient randomized study reported that the survival rate at year two was 25 percent for patients in the vaccine group verses the control group. 

According to the article, rindopepimut targets a mutant protein, EGFRvIII, which is present in about 25-30 percent of GBM patients. Patients in the study carried this mutation, and 30 percent of the patients responded to the vaccine. 

Michael Lim, director of brain tumor immunotherapy at John Hopkins Medicine, Baltimore, and not affiliated with the study, said, “They took a group of patients that are probably the toughest to treat. The fact that they showed any sort of signal is very intriguing.”

To read the full article, click here